NCT04041570View on ClinicalTrials.gov

Ebola Sudan Chimpanzee Adenovirus Vector Vaccine in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 2, 2019

Primary Completion Date

September 7, 2020

Study Completion Date

September 7, 2020

Conditions
Ebola Virus
Interventions
BIOLOGICAL

cAd3-EBO S vaccine

The recombinant chimpanzee adenovirus Type 3-vectored Ebola vaccine, VRC-EBOADC086-00-VP (cAd3-EBO S), is composed of a cAd3 vector that encodes Ebola Sudan wild type glycoprotein (WT GP).

Trial Locations (1)

Unknown

Makerere University-Walter Reed Project, Kampala

All Listed Sponsors
collaborator

US Military HIV Research Program

NETWORK

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT04041570 - Ebola Sudan Chimpanzee Adenovirus Vector Vaccine in Healthy Adults | Biotech Hunter | Biotech Hunter